基本信息 药品名称 CYB003 药品类别 创新药; 化药; 小分子; G蛋白偶联受体 靶点 serotonin receptor 2A 作用机制 5-HT2A receptor激动剂 药品简介 -- 研发机构 Cybin ;Catalent (Novo Nordisk) 最高研发阶段 全球: III期临床 中国: 临床前 审评审批类型 -- 外置链接 -- 了解药物更多情报 登录...
innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of
the expected timeline for the shipment of CYB003 capsules to clinical sites in Q1 2024; anticipated timeline for submission of data to the FDA; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regime...
Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, try...
benefits of the Company’s multiple psilocybin program CYB001, CYB002, and CYB003, the potential benefits of psilocybin, and the development of the Company’s proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens in order to advance...
As PGRMC1 has been reported to regulate the expression and activities of cytochrome P450 proteins (CYPs), we examined the role of CYB5D2 in regulating the activities of CYPs involved in sterol synthesis (CYP51A1) and drug metabolism (CYP3A4). CYB5D2 co-localizes with cytochrome P450 ...
Print Clinical researchPhase III MORE ON THIS TOPIC Vaccines FDA Pauses Study of BioNTech’s Malaria Shot as Problems for Vaccine Space Mount March 5, 2025 · 2 min read · Tristan Manalac Cancer BeiGene Gets Yet Another Label Expansion for PD-1 Drug Tevimbra ...
the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on...